A multiple-sclerosis drug that was at the center of Sanofi SA's $20 billion takeover battle for Genzyme Corp. three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide.

The U.S. Food and Drug Administration is expected to decide later this year whether to approve the drug, Paris-based Sanofi said.

The drug, Lemtrada, was developed by Genzyme, the Cambridge, Mass., biotechnology...